zynerba
pharmaceuticals
receives
orphan
drug
designation
cannabidiol
treatment
deletion
syndrome
devon
globe
newswire
zynerba
pharmaceuticals
nasdaq
zyne
leader
innovative
transdermal
cannabinoid
therapies
rare
neuropsychiatric
disorders
today
announced
food
drug
administration
granted
orphan
drug
designation
cannabidiol
cbd
use
treating
deletion
syndrome
rare
midline
condition
featuring
physical
abnormalities
debilitating
neuropsychiatric
behavioral
symptoms
including
anxiety
withdrawn
behavior
social
interaction
problems
zynerba
committed
developing
cbd
gel
certain
rare
conditions
including
urgent
need
new
innovative
therapeutics
said
armando
anido
chairman
chief
executive
officer
zynerba
pleased
fda
shares
sense
urgency
regarding
development
effective
therapeutics
important
patient
population
receipt
designation
represents
another
important
milestone
us
look
forward
working
closely
fda
develop
zygel
pediatric
adolescent
patients
expeditiously
orphan
drug
designation
orphan
drug
act
oda
fda
may
grant
orphan
drug
designation
drugs
intended
treat
rare
diseases
conditions
affect
fewer
individuals
first
nda
applicant
receive
fda
approval
particular
active
moiety
treat
particular
disease
fda
orphan
drug
designation
entitled
various
incentives
oda
including
tax
credits
qualified
clinical
testing
waiver
new
drug
application
nda
biologics
license
application
bla
user
fees
eligibility
exclusive
marketing
period
drug
use
upon
marketing
approval
deletion
syndrome
second
common
chromosomal
disorder
syndrome
caused
small
missing
piece
chromosome
deletion
occurs
near
middle
chromosome
location
designated
considered
condition
physical
symptoms
including
characteristic
palate
abnormalities
heart
defects
immune
dysfunction
esophageal
gi
issues
well
debilitating
neuropsychiatric
behavioral
challenges
anxiety
among
common
neuropsychiatric
symptoms
researchers
found
children
anxiety
linked
poorer
adaptive
behaviors
communication
skills
affect
daily
life
children
also
experience
withdrawn
behavior
adhd
cognitive
impairment
autism
spectrum
disorder
affect
communication
social
interaction
later
life
increased
risk
developing
mental
illnesses
schizophrenia
estimated
occurs
one
one
live
births
suggesting
approximately
people
living
zynerba
pharmaceuticals
zynerba
pharmaceuticals
leader
transdermal
cannabinoid
therapies
rare
neuropsychiatric
disorders
committed
improving
lives
patients
families
living
severe
chronic
health
conditions
including
fragile
x
syndrome
autism
spectrum
disorder
deletion
syndrome
heterogeneous
group
rare
epilepsies
known
developmental
epileptic
encephalopathies
learn
follow
us
twitter
zynerbapharma
cautionary
note
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
may
cases
use
terms
predicts
believes
potential
proposed
continue
estimates
anticipates
expects
plans
intends
may
could
might
words
convey
uncertainty
future
events
outcomes
identify
statements
statements
subject
numerous
important
factors
risks
uncertainties
may
cause
actual
events
results
differ
materially
company
current
expectations
management
expectations
therefore
statements
press
release
could
also
affected
risks
uncertainties
relating
number
factors
including
following
company
cash
cash
equivalents
may
sufficient
support
operating
plan
long
anticipated
company
expectations
projections
estimates
regarding
expenses
future
revenue
capital
requirements
incentive
tax
credit
eligibility
collectability
timing
availability
need
additional
financing
company
ability
obtain
additional
funding
support
clinical
development
programs
results
cost
timing
company
clinical
development
programs
including
delays
clinical
trials
relating
enrollment
site
initiation
clinical
results
company
product
candidates
may
replicated
continue
occur
additional
trials
may
otherwise
support
development
specified
indication
actions
advice
food
drug
administration
foreign
regulatory
agencies
may
affect
design
initiation
timing
continuation
progress
clinical
trials
result
need
additional
clinical
trials
company
ability
obtain
maintain
regulatory
approval
product
candidates
labeling
approval
company
reliance
third
parties
assist
conducting
clinical
trials
product
candidates
delays
interruptions
failures
manufacture
supply
company
product
candidates
company
ability
commercialize
product
candidates
size
growth
potential
markets
company
product
candidates
company
ability
service
markets
company
ability
develop
sales
marketing
capabilities
whether
alone
potential
future
collaborators
rate
degree
market
acceptance
company
product
candidates
company
expectations
regarding
ability
obtain
adequately
maintain
sufficient
intellectual
property
protection
product
candidates
timing
outcome
current
future
legal
proceedings
extent
health
epidemics
outbreaks
communicable
diseases
including
could
disrupt
operations
adversely
affect
business
financial
conditions
list
exhaustive
risks
described
company
periodic
reports
including
annual
report
form
quarterly
reports
form
current
reports
form
filed
furnished
securities
exchange
commission
available
statements
company
makes
press
release
speak
date
press
release
company
assumes
obligation
update
statements
whether
result
new
information
future
events
otherwise
date
press
release
investor
contact
william
roberts
vice
president
investor
relations
corporate
communications
zynerba
pharmaceuticals
robertsw
